- Home
- TRIP vs OCUL Comparison
TRIP vs OCUL Comparison
Compare TRIP & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- OCUL
- Stock Information
- Founded
- TRIP 2000
- OCUL 2006
- Country
- TRIP United States
- OCUL United States
- Employees
- TRIP N/A
- OCUL N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- OCUL Health Care
- Exchange
- TRIP Nasdaq
- OCUL Nasdaq
- Market Cap
- TRIP 2.1B
- OCUL 2.3B
- IPO Year
- TRIP 2011
- OCUL 2014
- Fundamental
- Price
- TRIP $15.88
- OCUL $11.41
- Analyst Decision
- TRIP Hold
- OCUL Strong Buy
- Analyst Count
- TRIP 9
- OCUL 9
- Target Price
- TRIP $17.03
- OCUL $22.13
- AVG Volume (30 Days)
- TRIP 2.8M
- OCUL 3.2M
- Earning Date
- TRIP 11-05-2025
- OCUL 11-13-2025
- Dividend Yield
- TRIP N/A
- OCUL N/A
- EPS Growth
- TRIP 165.58
- OCUL N/A
- EPS
- TRIP 0.46
- OCUL N/A
- Revenue
- TRIP $1,870,000,000.00
- OCUL $56,664,000.00
- Revenue This Year
- TRIP $7.36
- OCUL N/A
- Revenue Next Year
- TRIP $7.41
- OCUL $18.87
- P/E Ratio
- TRIP $34.51
- OCUL N/A
- Revenue Growth
- TRIP 3.03
- OCUL N/A
- 52 Week Low
- TRIP $10.43
- OCUL $5.79
- 52 Week High
- TRIP $20.16
- OCUL $13.85
- Technical
- Relative Strength Index (RSI)
- TRIP 37.04
- OCUL 41.26
- Support Level
- TRIP $16.54
- OCUL $10.63
- Resistance Level
- TRIP $17.71
- OCUL $12.88
- Average True Range (ATR)
- TRIP 0.91
- OCUL 0.69
- MACD
- TRIP -0.31
- OCUL -0.17
- Stochastic Oscillator
- TRIP 11.75
- OCUL 33.33
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.